GP Pharm announces European approval of Lutrate Depot 22.5 mg , a new trimestral Leuprolide depot formulation for the palliative treatment of advanced prostate cancer

Publicado por en 14 May, 2015 en Noticias | Sin comentarios

GP Pharm announces European approval of Lutrate Depot 22.5 mg , a new trimestral Leuprolide depot formulation for the palliative treatment of advanced prostate cancer

GP-Pharm announced last 8th May 2015, that its Lutrate Depot 22.5 mg has been approved through an EU decentralized procedure. Lutrate Depot 22.5 mg is a new trimestral Leuprolide depot formulation for the palliative treatment of advanced prostate cancer.

Lutrate is based on a by GP-Pharm developed patented technological platform of microspheres.
During its pivotal clinical trial phase III Lutrate Depot 22.5 mg achieved excellent castration levels in patients.  Patients with prostate cancer will  have  the  opportunity  to  benefit  from  the  most  effective  sustained released  formulation.

Lutrate Depot  22.5  mg is  expected  to  become  available  in  Europe  during  the fourth quarter  of 2015.

Lutrate Depot 22.5 mg is the second Leuprolide depot formulation of GP Pharm after the successful registration of Lutrate Depot 3.75 mg in 2010 strengthens its urology and oncology portfolio.

Dejar una Respuesta

Tu dirección de correo electrónico no será publicada.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies